vs
EXACT SCIENCES CORP（EXAS）与SSR MINING INC.（SSRM）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是SSR MINING INC.的1.7倍（$878.4M vs $521.7M），SSR MINING INC.净利率更高（34.8% vs -9.8%，领先44.6%），SSR MINING INC.同比增速更快（61.4% vs 23.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $106.4M），过去两年SSR MINING INC.的营收复合增速更高（50.5% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
SSR Mining Inc.（前身为白银标准资源公司）总部位于美国科罗拉多州丹佛，主营金、银、铜、铅、锌矿产开采，拥有阿根廷最大的银矿，同时在美洲全境及土耳其开展矿产勘探业务。2020年与阿拉瑟黄金合并后迁至丹佛，现任总裁兼首席执行官为罗德尼·P·安塔尔。
EXAS vs SSRM — 直观对比
营收规模更大
EXAS
是对方的1.7倍
$521.7M
营收增速更快
SSRM
高出38.3%
23.1%
净利率更高
SSRM
高出44.6%
-9.8%
自由现金流更多
EXAS
多$14.1M
$106.4M
两年增速更快
SSRM
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $521.7M |
| 净利润 | $-86.0M | $181.5M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 38.8% |
| 净利率 | -9.8% | 34.8% |
| 营收同比 | 23.1% | 61.4% |
| 净利润同比 | 90.1% | 3166.6% |
| 每股收益（稀释后） | $-0.45 | $0.84 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSSRM
| Q4 25 | $878.4M | $521.7M | ||
| Q3 25 | $850.7M | $385.8M | ||
| Q2 25 | $811.1M | $405.5M | ||
| Q1 25 | $706.8M | $316.6M | ||
| Q4 24 | $713.4M | $323.2M | ||
| Q3 24 | $708.7M | $257.4M | ||
| Q2 24 | $699.3M | $184.8M | ||
| Q1 24 | $637.5M | $230.2M |
净利润EXASSSRM
| Q4 25 | $-86.0M | $181.5M | ||
| Q3 25 | $-19.6M | $65.4M | ||
| Q2 25 | $-1.2M | $90.1M | ||
| Q1 25 | $-101.2M | $58.8M | ||
| Q4 24 | $-864.6M | $5.6M | ||
| Q3 24 | $-38.2M | $10.6M | ||
| Q2 24 | $-15.8M | $9.7M | ||
| Q1 24 | $-110.2M | $-287.1M |
毛利率EXASSSRM
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASSSRM
| Q4 25 | -9.4% | 38.8% | ||
| Q3 25 | -3.0% | 21.6% | ||
| Q2 25 | -0.3% | 26.9% | ||
| Q1 25 | -13.6% | 21.1% | ||
| Q4 24 | -122.8% | 10.6% | ||
| Q3 24 | -5.6% | 3.5% | ||
| Q2 24 | -3.8% | 5.8% | ||
| Q1 24 | -16.7% | -163.5% |
净利率EXASSSRM
| Q4 25 | -9.8% | 34.8% | ||
| Q3 25 | -2.3% | 17.0% | ||
| Q2 25 | -0.1% | 22.2% | ||
| Q1 25 | -14.3% | 18.6% | ||
| Q4 24 | -121.2% | 1.7% | ||
| Q3 24 | -5.4% | 4.1% | ||
| Q2 24 | -2.3% | 5.2% | ||
| Q1 24 | -17.3% | -124.7% |
每股收益（稀释后）EXASSSRM
| Q4 25 | $-0.45 | $0.84 | ||
| Q3 25 | $-0.10 | $0.31 | ||
| Q2 25 | $-0.01 | $0.42 | ||
| Q1 25 | $-0.54 | $0.28 | ||
| Q4 24 | $-4.69 | $0.03 | ||
| Q3 24 | $-0.21 | $0.05 | ||
| Q2 24 | $-0.09 | $0.05 | ||
| Q1 24 | $-0.60 | $-1.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $575.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $3.5B |
| 总资产 | $5.9B | $6.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASSSRM
| Q4 25 | $964.7M | $575.6M | ||
| Q3 25 | $1.0B | $445.4M | ||
| Q2 25 | $858.4M | $438.5M | ||
| Q1 25 | $786.2M | $341.3M | ||
| Q4 24 | $1.0B | $417.3M | ||
| Q3 24 | $1.0B | $365.8M | ||
| Q2 24 | $946.8M | $384.4M | ||
| Q1 24 | $652.1M | $492.0M |
总债务EXASSSRM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $228.6M | ||
| Q3 24 | — | $228.3M | ||
| Q2 24 | — | $228.0M | ||
| Q1 24 | — | $228.7M |
股东权益EXASSSRM
| Q4 25 | $2.4B | $3.5B | ||
| Q3 25 | $2.5B | $3.3B | ||
| Q2 25 | $2.5B | $3.3B | ||
| Q1 25 | $2.4B | $3.2B | ||
| Q4 24 | $2.4B | $3.1B | ||
| Q3 24 | $3.2B | $3.1B | ||
| Q2 24 | $3.2B | $3.1B | ||
| Q1 24 | $3.1B | $3.1B |
总资产EXASSSRM
| Q4 25 | $5.9B | $6.1B | ||
| Q3 25 | $5.9B | $5.9B | ||
| Q2 25 | $5.8B | $5.8B | ||
| Q1 25 | $5.7B | $5.6B | ||
| Q4 24 | $5.9B | $5.2B | ||
| Q3 24 | $6.7B | $5.1B | ||
| Q2 24 | $6.7B | $5.2B | ||
| Q1 24 | $6.4B | $5.3B |
负债/权益比EXASSSRM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.07× | ||
| Q1 24 | — | 0.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $172.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $106.4M |
| 自由现金流率自由现金流/营收 | 13.7% | 20.4% |
| 资本支出强度资本支出/营收 | 3.6% | 12.6% |
| 现金转化率经营现金流/净利润 | — | 0.95× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $241.6M |
8季度趋势，按日历期对齐
经营现金流EXASSSRM
| Q4 25 | $151.7M | $172.1M | ||
| Q3 25 | $219.9M | $57.2M | ||
| Q2 25 | $89.0M | $157.8M | ||
| Q1 25 | $30.8M | $84.8M | ||
| Q4 24 | $47.1M | $95.0M | ||
| Q3 24 | $138.7M | $-1.3M | ||
| Q2 24 | $107.1M | $-78.1M | ||
| Q1 24 | $-82.3M | $24.6M |
自由现金流EXASSSRM
| Q4 25 | $120.4M | $106.4M | ||
| Q3 25 | $190.0M | $-2.4M | ||
| Q2 25 | $46.7M | $98.4M | ||
| Q1 25 | $-365.0K | $39.3M | ||
| Q4 24 | $10.7M | $56.4M | ||
| Q3 24 | $112.6M | $-34.1M | ||
| Q2 24 | $71.2M | $-116.3M | ||
| Q1 24 | $-120.0M | $-9.4M |
自由现金流率EXASSSRM
| Q4 25 | 13.7% | 20.4% | ||
| Q3 25 | 22.3% | -0.6% | ||
| Q2 25 | 5.8% | 24.3% | ||
| Q1 25 | -0.1% | 12.4% | ||
| Q4 24 | 1.5% | 17.5% | ||
| Q3 24 | 15.9% | -13.2% | ||
| Q2 24 | 10.2% | -62.9% | ||
| Q1 24 | -18.8% | -4.1% |
资本支出强度EXASSSRM
| Q4 25 | 3.6% | 12.6% | ||
| Q3 25 | 3.5% | 15.4% | ||
| Q2 25 | 5.2% | 14.7% | ||
| Q1 25 | 4.4% | 14.4% | ||
| Q4 24 | 5.1% | 11.9% | ||
| Q3 24 | 3.7% | 12.7% | ||
| Q2 24 | 5.1% | 20.7% | ||
| Q1 24 | 5.9% | 14.8% |
现金转化率EXASSSRM
| Q4 25 | — | 0.95× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 1.75× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | — | 17.10× | ||
| Q3 24 | — | -0.13× | ||
| Q2 24 | — | -8.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SSRM
| Gold | $369.3M | 71% |
| Concentrate Sales | $124.4M | 24% |
| Other | $19.1M | 4% |
| Lead | $9.0M | 2% |
